News
MYGN
15.78
-2.41%
-0.39
Myriad Genetics price target lowered to $24 from $34 at Scotiabank
TipRanks · 1d ago
Myriad Genetics expands access to at-home early fetal sex DNA test
TipRanks · 1d ago
Myriad Genetics (MYGN) Gets a Buy from Scotiabank
TipRanks · 1d ago
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price
Simply Wall St · 1d ago
MYRIAD GENETICS INC <MYGN.O>: SCOTIABANK CUTS TARGET PRICE TO $24 FROM $34
Reuters · 2d ago
U.S. RESEARCH ROUNDUP-Cable One, Neurogene, Topbuild
Reuters · 2d ago
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Dow Jones · 3d ago
Myriad Genetics Price Target Cut to $24.00/Share From $30.00 by Piper Sandler
Dow Jones · 3d ago
Piper Sandler Maintains Neutral on Myriad Genetics, Lowers Price Target to $24
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Jazz Pharmaceuticals (JAZZ)
TipRanks · 3d ago
Myriad Genetics price target lowered to $24 from $30 at Piper Sandler
TipRanks · 3d ago
Weekly Report: what happened at MYGN last week (1104-1108)?
Weekly Report · 3d ago
Myriad Genetics: Overcoming Setbacks with Strategic Resilience and Growth Prospects
TipRanks · 3d ago
Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St · 5d ago
Myriad Genetics Reports Solid Q3 2024 Growth Amid Challenges
TipRanks · 5d ago
Myriad Genetics, Inc. Reports Quarterly Results for the Period Ended September 30, 2024
Press release · 5d ago
Myriad Genetics price target lowered to $20 from $30 at TD Cowen
TipRanks · 6d ago
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View
NASDAQ · 6d ago
MYRIAD GENETICS INC <MYGN.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $30 FROM $40
Reuters · 6d ago
Myriad Genetics Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 6d ago
More
Webull provides a variety of real-time MYGN stock news. You can receive the latest news about Myriad Genetics through multiple platforms. This information may help you make smarter investment decisions.
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.